"Sitagliptin dose adjustments are recommended for patients with moderate or severe RI [renal insufficiency] or ESRD [end-stage renal disease]"

By  

Inpharma, Vol. 1, Iss. 1601, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)

By Zoccali Carmine   Mallamaci Francesca   Tripepi Giovanni  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 131-135

Springer Publishing Company

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite